Alkermes PLC (id:7362 ALKS)
29.50 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/24/2024 8:00:02 AM)
Exchange closed, opens in 1 hour 29 minutes
About Alkermes PLC
Market Capitalization 4.86B
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Headquarters (address) |
Connaught House Dublin D04 C5Y6 Ireland |
Phone | 353 1 772 8000 |
Website | https://www.alkermes.com |
Employees | 2K |
Sector | Healthcare |
Industry | Drug Manufacturers Specialty & Generic |
Ticker | ALKS |
Exchange | NASDAQ Stock Exchange |
Currency | USD |
52 week range | 22.90 - 32.88 |
Market Capitalization | 4.86B |
P/E trailing | 13.11 |
P/E forward | 14.94 |
Price/Sale | 3.23 |
Price/Book | 3.76 |
Beta | 3.00 |
EPS | 2.29 |
EPS Ireland (ID:161, base:52) | 2.88 |